2017年10月,FDA批准阿斯利康的艾塞那肽缓释注射剂(Bydureon BCise)用于2型糖尿病患者的治疗。本品适用于已使用一种或多种口服药物且控制饮食和锻炼后仍无法控制血糖的2型糖尿病成人患者。本品每周一次,单剂量自动注射。与其他胰高血糖素样肽-1(GLP-1)受体激动剂不同的是,本品有一个独特的、持续释放的微球传递系统,能够持续提供有效成分,帮助患者达到并保持血糖的稳定状态。这个创新剂型被证明可降低患者血糖水平, In October 2017, the FDA approved AstraZeneca’s sustained-release injection of exenatide (Bydureon BCise) for the treatment of type 2 diabetes. This product is suitable for adults with type 2 diabetes who have been using one or more oral medications and are unable to control their blood sugar after diet and exercise. This product once a week, a single dose auto-injection. Unlike other glucagon-like peptide-1 (GLP-1) receptor agonists, this product has a unique, sustained-release microsphere delivery system that continuously delivers active ingredients to help patients achieve and maintain blood sugar Steady state. This innovative dosage form has been shown to lower blood glucose levels in patients,